Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عمان
وزارة الصحة
مركز سلامة الدواء
مسقط

To:
Pharmacist Incharge, Armed Forces Hospital (AT Khoudh & Salalah)
Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director of Pharmaceutical Care, DGHS, Muscat Governorate
Director of Pharmaceutical Care, DGHS, Al Dakhliya Governorate
Director of Pharmaceutical Care, DGHS, South Batinah Governorate
Director of Pharmaceutical Care, DGHS, North Batinah Governorate
Director of Pharmaceutical Care, DGHS, AI Dhahira Governorate
Director of Pharmaceutical Care, DGHS, North Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, South Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, Musandam Governorate
Director of Pharmaceutical Care, DGHS, Dhofar Governorate
Director of Pharmaceutical Care, DGHS, Al Wusta Governorate
Director of Pharmaceutical Care, DGHS, Buraimi Governorate
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
HOD, Pharmacy Department, Sultan Qaboos University Hospital
Pharmacist Incharge, Royal Oman Police
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman
All Private Pharmacies & Drug Stores

After Compliments,
Kindly find attached our Circular No 65 **dated** 28**/06/2026 Regarding Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib).**

Copy to:

- **Director of Pharmacovigilance Department, DSC**
- **Director of Medicine Registration Department, DSC**
- **Director of Regulatory Compliance Department, DSC**
- **Director of Central Quality Control Lab., DSC**
- **Director of Medical Device Department, DSC**
- **Section Head of Medicine Safety Evaluation**
- **Section Head of Quality Problems and Medication Errors.**
- **Section Head of Pharmacovigilance**
- **Section Head of Clinical Trials**

DSC
مركز سلامة الدواء
Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om

Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عمان
وزارة الصحة
مركز سلامة الدواء
مسقط

Circular No. 65 **/2026**

12 **-01-1448 H**
28 **-06-2026**

Subject: Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib)

The Drug Safety Center (DSC) would like to share a new safety information published by **World Health Organization (WHO)** regarding **Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib).**

JAKAVI® (ruxolitinib) is a kinase (JAK) inhibitor indicated for the treatment of selected hematological disorders including myelofibrosis, polycythemia vera, and graft-versus-host disease.

According to the WHO Medical Product Alert, three falsified batches of JAKAVI® have been identified in the **Islamic Republic of Iran, Türkiye, and the Russian Federation** and reported to WHO in **May 2026**. A falsified version of JAKAVI (ruxolitinib) 15mg & 20mg has been identified in Eastern Mediterranean and European regions. The falsified products have been illicitly sold to patients via online platforms and, in at least one instance, have also been supplied to patients from a pharmacy.

The genuine manufacturer (Novartis) has confirmed that the following batch numbers are **not genuine** and should be considered falsified:

- **JAKAVI® 20 mg** – Batch **AVT50** (Expiry: **12/2028**)
- **JAKAVI® 15 mg** – Batch **FNR06** (Expiry: **07/2027**)
- **JAKAVI® 15 mg** – Batch **SGL04** (Expiry: **11/2028**)

Analysis conducted by the genuine manufacturer on a sample of the **falsified JAKAVI 20 mg (AVT50)** identified in **Türkiye** confirmed the **absence** of the stated active ingredient, ruxolitinib.

The genuine manufacturer also reported several visual discrepancies in the packaging. In particular, blister strips from **falsified cartons of JAKAVI batches AVT50 and SGL04 do not display a batch number**.

Risk:
The **use of these falsified products** may pose significant risks to patient health. These falsified products have **not yet undergone laboratory analysis**, they may contain **no active ingredient, incorrect ingredients, or harmful substances**. Their use may lead to **treatment failure**, resulting in progression of serious disease and an increased risk of death due to lack of therapeutic effect. Patients receiving JAKAVI (ruxolitinib) often have weakened immune systems as a result of their condition. This makes them particularly vulnerable to ineffective or falsified products which may result in rapid deterioration and severe clinical outcomes. **Prompt detection and removal of these falsified products** from the supply chain is **essential** to prevent harm to patients.

DSC مركز سلامة الدواء Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om

Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عمان
وزارة الصحة
مركز سلامة الدواء
مسقط

Advice for Healthcare Professionals:

- Be aware of the WHO alert regarding falsified JAKAVI® (ruxolitinib).
- Verify the authenticity of JAKAVI® products before dispensing or administration.
- Do not dispense or use products bearing batch numbers **AVT50, FNR06, or SGL04**.
- Obtain medicines only through authorized and licensed suppliers.
- Isolate any suspected products and follow the established reporting procedures.

Advice for Healthcare Professionals to Provide to Patients:

- Obtain JAKAVI® only from authorized healthcare facilities and licensed pharmacies.
- Do not purchase medicines from unauthorized online sources.
- Seek medical advice immediately if your medicine appears suspicious or if you experience an unexpected lack of therapeutic effect.
- Do not discontinue treatment without consulting your healthcare provider.

DSC
مركز سلامة الدواء
Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om

Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عمان
وزارة الصحة
مركز سلامة الدواء
مسقط

نتقدم بثقة
Moving Forward with Confidence

رؤية عمان 2040

Annex: Products subject of WHO Medical Product Alert N°2/2026

Product name	JAKAVI (ruxolitinib) 20mg		JAKAVI (ruxolitinib) 15mg	
Batch	AVT50		FNR06	SGL04
Expiry	12 . 2028		07 . 2027	11 . 2028
Identified in	Islamic Republic of Iran	Türkiye	Russian Federation	Türkiye
Stated manufacturer	NOVARTIS			

Available Photographs

Batch AVT50 identified in the Islamic Republic of Iran



DSC
مركز سلامة الدواء
Drug Safety Center

ISO 9001:2015 CERTIFIED

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om

Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عمان
وزارة الصحة
مركز سلامة الدواء
مسقط



Call to report:

Ruxolitinib (JAKAVI) is registered in Oman. Healthcare professionals, patients, and caregivers are requested to report any suspected falsified medical products, quality defects, unexpected lack of therapeutic effect, or adverse drug reactions through the Ministry of Health e-Portal to the Pharmacovigilance Department under the Drug Safety Center.

Ph. Ibrahim Nasser Al Rashdi
Director General

DSC مركز سلامة الدواء Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om